SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-031482
Filing Date
2023-03-13
Accepted
2023-03-13 06:45:56
Documents
13
Period of Report
2023-03-13
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm239332d1_8k.htm   iXBRL 8-K 29091
  Complete submission text file 0001104659-23-031482.txt   247334

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20230313.xsd EX-101.SCH 3508
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20230313_def.xml EX-101.DEF 26897
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20230313_lab.xml EX-101.LAB 36508
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20230313_pre.xml EX-101.PRE 25521
7 EXTRACTED XBRL INSTANCE DOCUMENT tm239332d1_8k_htm.xml XML 5158
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 23725638
SIC: 2834 Pharmaceutical Preparations